“In addition, on December 15, 2021, in connection with the termination of Mr. Kern, the Board authorized and approved the appointment of Mark Corrao, age 64, as Chief Financial Officer of the Company.”
///
“Mr. Corrao served as the Chief Financial Officer for Generex Biotechnology Corporation (OTCQB:GNBT), a drug development company, and its subsidiaries.”
https://www.google.com/amp/s/www.marketscreen...-37390119/
He does sometimes hold different CFO roles simultaneously, as the head of the CFO Group. I wonder if his new client is aware that at Generex he’s CFO of a company delinquent in SEC financial reporting?